Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Glen S. Kwon has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer

    by Rae Hyung Kang, Morteza Rasoulianboroujeni, Maryam Kianpour, Lauren Repp, Suzanne M. Ponik, Glen S. Kwon

    Triple-negative breast cancer (TNBC) remains a significant clinical challenge due to its high aggressiveness, poor prognosis, and lack of targeted therapies. Combining paclitaxel (PTX) with rapamycin (RAP), a PI3K/AKT/mTOR pathway inhibitor, has shown promise in preclinical and clinical studies, but the approach is limited by pharmacokinetic disparities and toxicity concerns. Here, we introduce Rapaxane, a formulation composed of polymeric micelles coloaded with oligo(lactic acid)8 conjugated prodrugs of PTX (oLA8-PTX) and RAP (oLA8-RAP) at an optimized synergistic ratio (5:1). We evaluated the efficacy of Rapaxane in vitro and in preclinical TNBC models, comparing it to the benchmark formulation Abraxane, the combination of parent drugs, and monotherapies using the prodrugs. In vitro, Rapaxane demonstrated notable cytotoxicity against the 4T1 and MDA-MB-231 TNBC cell lines. Ratiometric encapsulation, stability, synchronized drug release, and conversion were confirmed using dynamic light scattering (DLS) and reverse-phase high-performance liquid chromatography (RP-HPLC). Hemolysis assays indicated negligible toxicity, confirming the safety of Rapaxane for intravenous administration. In vivo, Rapaxane significantly reduced tumor growth and metastasis while improving survival rates in subcutaneous and orthotopic TNBC mouse models. Histological analysis using H&E staining, complemented by Ki-67 immunohistochemical staining, demonstrated effective inhibition of lung metastasis in Rapaxane-treated groups compared to control groups. Rapaxane's ability to maintain precise ratiometric dosing, sustain drug release, and enhance therapeutic efficacy while mitigating adverse effects underscores its potential as a next-generation therapy for TNBC. This study highlights the feasibility of nanotechnology-based ratiometric drug delivery systems in overcoming the limitations of conventional combination therapies, paving the way for more effective treatment options for aggressive cancers like TNBC.


  • Top Cited Papers
    Open Access

    From Conventional to Next-Generation Strategies: Recent Advances in Polymeric Micelle Preparation for Drug Delivery

    by Suhyeon Cho, Morteza Rasoulianboroujeni, Rae Hyung Kang, Glen S. Kwon

    Polymeric micelles are promising nanocarriers for hydrophobic drug delivery, offering enhanced solubility, circulation time, and targeted release. This review presents a comprehensive evaluation of micelle preparation strategies, spanning conventional methods such as direct dissolution, dialysis, and thin-film hydration to emerging techniques including microfluidics, supercritical fluids, stimuli-responsive systems, and PEG-assisted assembly. Each method is compared in terms of scalability, reproducibility, solvent use, and regulatory compatibility. Among them, PEG-assisted methods show particular promise due to their simplicity and industrial readiness. We also explore the impact of fabrication strategy on drug loading, stability, and therapeutic efficacy across applications in cancer, infection, and inflammation. Finally, the review discusses key challenges in storage, manufacturing, and regulation, and highlights potential solutions through Quality-by-Design and scalable process integration. These insights provide guidance for the rational development of clinically translatable micelle-based drug delivery systems.


  • Open Access

    Inhibiting fibronectin assembly in the breast tumor microenvironment increases cell death and improves response to doxorubicin

    by Metti K. Gari, Hye Jin Lee, David R. Inman, Brian M. Burkel, Margaret A. Highland, Glen S. Kwon, Nikesh Gupta, Suzanne M. Ponik

    Purpose Effective therapies for solid tumors, including breast cancers, are hindered by several roadblocks that can be largely attributed to the fibrotic extracellular matrix (ECM). Fibronectin (FN) is a highly upregulated ECM component in the fibrotic tumor stroma and is associated with poor patient prognosis. This study aimed to investigate the therapeutic potential of an anti-fibrotic peptide that specifically targets FN and blocks the fibrillar assembly of FN. Methods To target FN, we used PEGylated Functional Upstream Domain (PEG-FUD), which binds to the 70 kDa N-terminal region of FN with high affinity, localizes to mammary tumors, and potently inhibits FN assembly in vitro and in vivo. Here, we used the 4T1 tumor model to investigate the efficacy and mechanisms of PEG-FUD to inhibit tumor growth. Results Our data demonstrates that PEG-FUD monotherapy reduces tumor growth without systemic toxicity. Analysis of the tumor microenvironment revealed that PEG-FUD effectively inhibited FN matrix assembly within tumors and reduced adhesion-mediated signaling through α5 integrin and FAK leading to enhanced tumor cell death. Notably, signaling through FAK has been associated with resistance mechanisms to doxorubicin (DOX). Therefore, we tested the combination of PEG-FUD and Dox, which significantly reduced tumor growth by 60% compared to vehicle control and 30% compared to Dox monotherapy. Conclusions Our findings demonstrate that PEG-FUD significantly modifies the peritumoral ECM of breast cancer, leading to increased tumor cell death, and potentiates the efficacy of conventional breast cancer therapy.


  • Crystallization of supersaturated PEG-b-PLA for the production of drug-loaded polymeric micelles

    by Morteza Rasoulianboroujeni, Rae Hyung Kang, Maraya Klukas, Glen S. Kwon


  • Entropy-Driven Liquid–Liquid Phase Separation Transition to Polymeric Micelles

    by Morteza Rasoulianboroujeni, Melgardt M. de Villiers, Glen S. Kwon

    In recent years, liquid-liquid phase separation (LLPS) has been recognized to act as a precursor to self-assembly in amphiphilic systems. In this study, we propose the use of entropy-driven LLPS to obtain a tunable precursor for polymeric micelle formation. In this new approach, an oligomer is utilized as a nonselective solvent for the block copolymer, allowing for the tuning of entropy and subsequent LLPS. A comprehensive model was developed using mean-field lattice theory to predict the conditions under which LLPS and micellization occur. The degree of polymerization of the solvent was found to have a significant impact on the phase behavior of the system, outweighing enthalpic contributions such as the interaction between the blocks of the copolymer and the solvent. Our model predicts that using a solvent with a degree of polymerization equal to or greater than 5 for a copolymer such as PEG4kDa-b-PLA2.2kDa will result in LLPS prior to complete micellization, regardless of the values of interaction parameters. It also suggests that phase-separated liquid and polymeric micelles can co-exist in such a mixture. We confirmed our model predictions using dynamic light scattering and phase microscopy when PEG200 was used as the solvent. Micellization for PEG4kDa-b-PLA2.2kDa/PEG200/water mixture occurred at 10-12% w/w water content, consistent with the model predictions. Furthermore, the LLPS-to-micelle transition was shown to be reversible by changing the temperature or water content, indicating that the phase-separated liquid may be in thermodynamic equilibrium with polymeric micelles.


  • Fibronectin-targeted FUD and PEGylated FUD peptides for fibrotic diseases

    by Hye Jin Lee, Bianca R. Tomasini-Johansson, Nikesh Gupta, Glen S. Kwon


  • Plasma Stability and Plasma Metabolite Concentration–Time Profiles of Oligo(Lactic Acid)8-Paclitaxel Prodrug Loaded Polymeric Micelles

    by Lauren Repp, Sarah L. Skoczen, Morteza Rasoulianboroujeni, Stephan T. Stern, Glen S. Kwon

    Paclitaxel (PTX) is a frequently prescribed chemotherapy drug used to treat a wide variety of solid tumors. Oligo(lactic acid)8-PTX prodrug (o(LA)8-PTX) lo


  • Multimodal imaging demonstrates enhanced tumor exposure of PEGylated FUD peptide in breast cancer

    by Hye Jin Lee, Metti K. Gari, David R. Inman, Zachary T. Rosenkrans, Brian M. Burkel, Aeli P. Olson, Jonathan W. Engle, Reinier Hernandez, Suzanne M. Ponik, Glen S. Kwon


  • Open Access

    Oligo(Lactic Acid)8-Docetaxel Prodrug-Loaded PEG-b-PLA Micelles for Prostate Cancer

    by Lauren Repp, Christopher J. Unterberger, Zhengqing Ye, John B. Feltenberger, Steven M. Swanson, Paul C. Marker, Glen S. Kwon

    Docetaxel (DTX) is among the most frequently prescribed chemotherapy drugs and has recently been shown to extend survival in advanced prostate cancer patients. However, the poor water solubility of DTX prevents full exploitation of this potent anticancer drug. The current marketed formulation, Taxotere®, contains a toxic co-solvent that induces adverse reactions following intravenous injection. Nano-sized polymeric micelles have been proposed to create safer, water-soluble carriers for DTX, but many have failed to reach the clinic due to poor carrier stability in vivo. In this study, we aimed to improve micelle stability by synthesizing an ester prodrug of DTX, oligo(lactic acid)8-docetaxel (o(LA)8-DTX), for augmented compatibility with the core of poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-PLA) micelles. Due to the enhancement of drug-carrier compatibility, we were able to load 50% (w/w) prodrug within the micelle, solubilize 20 mg/mL o(LA)8-DTX (~12 mg/mL DTX-equivalent) in aqueous media, and delay payload release. While the micelle core prohibited premature degradation, o(LA)8-DTX was rapidly converted to parent drug DTX through intramolecular backbiting (t1/2 = 6.3 h) or esterase-mediated degradation (t1/2 = 2.5 h) following release. Most importantly, o(LA)8-DTX micelles proved to be as efficacious but less toxic than Taxotere® in a preclinical mouse model of prostate cancer.